The introduction of monoclonal antibody that targets IL-1β has achieved success in the treatment of chronic immune-inflammatory diseases such as psoriasis, arthritis, or type 2 diabetes [28–30]. This evidence concerns the gene IL1B and type 2 diabetes mellitus.